OYST News and Press, Oyster Point Pharma Inc. From 11/07/22

Updated to add latest share price moves Oyster Point Pharma ( NASDAQ: OYST ), a company focused on eye disorders, announced Monday that Viatris ( NASDAQ: VTRS ) agreed to acquire it for $11.00 per share in cash plus a contingent value right (CVR). After a b...

Oyster Point Pharma ( NASDAQ: OYST ), a company focused on eye disorders, announced Monday that Viatris ( NASDAQ: VTRS ) agreed to acquire it for $11.00 per share in cash plus a contingent value right (CVR). The company said that its shareholders owning about 46% o...

Tender Offer to Acquire All Outstanding Shares of Oyster Point Pharma for $11.00 per Share, Plus a Contingent Value Right of Up To $2.00 per Share PRINCETON, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”), ...

PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST) a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that ...

PRINCETON, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pha...

PRINCETON, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc., (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class ph...

Summary Summers Value Partners is a boutique value manager that uses a focused, long-term approach to investing in areas of the market where most managers are unwilling or unable to participate. The Summers Value Fund LP (“the Fund”) returned -25.9% net in the first ...

PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the...

Oyster Point Pharma ( NASDAQ: OYST ) on Wednesday said its nasal spray Tyrvaya for the treatment of dry eye disease would now be covered by the largest Medicare pharmacy benefit manager (PBM) in the U.S. OYST did not name the PBM in its statement . Tyrvaya would be...

PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class phar...